Drug General Information |
Drug ID |
D07SDQ
|
Former ID |
DNC006900
|
Drug Name |
Curcumin
|
Drug Type |
Small molecular drug
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 3 |
[1],
[2]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C21H20O6
|
InChI |
InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
|
InChIKey |
VFLDPWHFBUODDF-FCXRPNKRSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
91276, 521754, 616319, 806710, 855880, 3139269, 7979963, 8136975, 8145866, 8719722, 10319004, 12013839, 12055808, 14803853, 17389087, 24892408, 24892983, 29203996, 44256039, 46493764, 48184781, 48414613, 48414614, 48423182, 48424998, 49854349, 49856278, 50104137, 50104138, 53788771, 56312449, 56313017, 56422380, 57288615, 57408903, 75735540, 81040856, 81054961, 81093229, 85286188, 85789755, 87565556, 87565557, 88806667, 92126156, 92709887, 93165931, 103961572, 104171337, 105852703
|
Target and Pathway |
Target(s) |
Carbonic anhydrase II |
Target Info |
Inhibitor |
[3]
|
Carbonic anhydrase XII |
Target Info |
Inhibitor |
[3]
|
Carbonic anhydrase VI |
Target Info |
Inhibitor |
[3]
|
Carbonic anhydrase IX |
Target Info |
Inhibitor |
[3]
|
Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[4]
|
Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[5]
|
Carbonic anhydrase XIV |
Target Info |
Inhibitor |
[3]
|
Carbonic anhydrase I |
Target Info |
Inhibitor |
[3]
|
DNA (cytosine-5)-methyltransferase |
Target Info |
Inhibitor |
[6]
|
Collagenase 3 |
Target Info |
Inhibitor |
[7]
|
DNA (cytosine-5)-methyltransferase 3B |
Target Info |
Inhibitor |
[6]
|
Xanthine dehydrogenase/oxidase |
Target Info |
Inhibitor |
[8]
|
Prostaglandin G/H synthase 1 |
Target Info |
Inhibitor |
[9]
|
MMP-9 |
Target Info |
Inhibitor |
[10]
|
Prostaglandin G/H synthase 2 |
Target Info |
Inhibitor |
[9]
|
Carbonic anhydrase IV |
Target Info |
Inhibitor |
[3]
|
Amyloid beta A4 protein |
Target Info |
Inhibitor |
[11]
|
Carbonic anhydrase |
Target Info |
Inhibitor |
[3]
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-6353:Purine nucleotides degradation
|
Urate biosynthesis/inosine 5'-phosphate degradation
|
Guanosine nucleotides degradation
|
Adenosine nucleotides degradation
|
Retinoate biosynthesis IIPWY66-374:C20 prostanoid biosynthesisPWY66-393:Aspirin-triggered lipoxin biosynthesis
|
Aspirin triggered resolvin D biosynthesis
|
C20 prostanoid biosynthesis
|
Aspirin triggered resolvin E biosynthesis
|
KEGG Pathway
|
Nitrogen metabolism
|
Proximal tubule bicarbonate reclamation
|
Collecting duct acid secretion
|
Gastric acid secretion
|
Pancreatic secretion
|
Bile secretionhsa00910:Nitrogen metabolismhsa00910:Nitrogen metabolismhsa00910:Nitrogen metabolismhsa00140:Steroid hormone biosynthesis
|
Linoleic acid metabolism
|
Retinol metabolism
|
Metabolism of xenobiotics by cytochrome P450
|
Drug metabolism - cytochrome P450
|
Drug metabolism - other enzymes
|
Metabolic pathways
|
Bile secretion
|
Chemical carcinogenesishsa00220:Arginine biosynthesis
|
Arginine and proline metabolism
|
Calcium signaling pathway
|
HIF-1 signaling pathway
|
Peroxisome
|
Salmonella infection
|
Pertussis
|
Leishmaniasis
|
Chagas disease (American trypanosomiasis)
|
Toxoplasmosis
|
Amoebiasis
|
Tuberculosis
|
Pathways in cancer
|
Small cell lung cancerhsa00910:Nitrogen metabolismhsa00910:Nitrogen metabolismhsa00270:Cysteine and methionine metabolism
|
MicroRNAs in cancerhsa00230:Purine metabolism
|
Caffeine metabolism
|
Peroxisomehsa00590:Arachidonic acid metabolism
|
Platelet activation
|
Serotonergic synapsehsa04668:TNF signaling pathway
|
Leukocyte transendothelial migration
|
Estrogen signaling pathway
|
Hepatitis B
|
Transcriptional misregulation in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Bladder cancerhsa00590:Arachidonic acid metabolism
|
NF-kappa B signaling pathway
|
VEGF signaling pathway
|
TNF signaling pathway
|
Retrograde endocannabinoid signaling
|
Serotonergic synapse
|
Ovarian steroidogenesis
|
Oxytocin signaling pathway
|
Regulation of lipolysis in adipocytes
|
Chemical carcinogenesis
|
Small cell lung cancerhsa00910:Nitrogen metabolism
|
Proximal tubule bicarbonate reclamationhsa04330:Notch signaling pathway
|
Alzheimer's disease
|
NetPath Pathway
|
IL4 Signaling Pathway
|
EGFR1 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
IL2 Signaling PathwayNetPath_13:IL1 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling PathwayNetPath_5:ID Signaling Pathway
|
TWEAK Signaling Pathway
|
Leptin Signaling Pathway
|
TNFalpha Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
TSH Signaling Pathway
|
TGF_beta_Receptor Signaling Pathway
|
IL5 Signaling Pathway
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
Plasminogen activating cascadeP02723:Adenine and hypoxanthine salvage pathway
|
Purine metabolismP00031:Inflammation mediated by chemokine and cytokine signaling pathwayP00004:Alzheimer disease-presenilin pathway
|
Plasminogen activating cascade
|
CCKR signaling map STP00019:Endothelin signaling pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
Toll receptor signaling pathway
|
CCKR signaling map ST
|
Pathway Interaction Database
|
HIF-1-alpha transcription factor networkil12_2pathway:IL12-mediated signaling events
|
Alpha9 beta1 integrin signaling events
|
ATF-2 transcription factor network
|
IL23-mediated signaling events
|
Signaling mediated by p38-alpha and p38-beta
|
HIF-1-alpha transcription factor networkcmyb_pathway:C-MYB transcription factor networkupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalinglysophospholipid_pathway:LPA receptor mediated events
|
Plasma membrane estrogen receptor signaling
|
Osteopontin-mediated events
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
Validated targets of C-MYC transcriptional activation
|
CXCR4-mediated signaling events
|
amb2 Integrin signaling
|
Syndecan-4-mediated signaling events
|
AP-1 transcription factor network
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
Syndecan-1-mediated signaling events
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
FGF signaling pathwaynfat_tfpathway:Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
S1P1 pathway
|
C-MYB transcription factor network
|
Calcium signaling in the CD4+ TCR pathway
|
PathWhiz Pathway
|
Caffeine Metabolism
|
Retinol MetabolismPW000565:Gastric Acid ProductionPW000015:Caffeine Metabolism
|
Purine MetabolismPW000044:Arachidonic Acid MetabolismPW000044:Arachidonic Acid Metabolism
|
Reactome
|
Erythrocytes take up carbon dioxide and release oxygen
|
Erythrocytes take up oxygen and release carbon dioxide
|
Reversible hydration of carbon dioxideR-HSA-1475029:Reversible hydration of carbon dioxideR-HSA-1475029:Reversible hydration of carbon dioxideR-HSA-1234158:Regulation of gene expression by Hypoxia-inducible Factor
|
Reversible hydration of carbon dioxideR-HSA-211981:Xenobiotics
|
Aflatoxin activation and detoxificationR-HSA-1222556:ROS production in response to bacteria
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1475029:Reversible hydration of carbon dioxideR-HSA-1237044:Erythrocytes take up carbon dioxide and release oxygen
|
Reversible hydration of carbon dioxideR-HSA-1442490:Collagen degradation
|
Degradation of the extracellular matrix
|
Activation of Matrix Metalloproteinases
|
Assembly of collagen fibrils and other multimeric structuresR-HSA-212300:PRC2 methylates histones and DNA
|
NoRC negatively regulates rRNA expression
|
DNA methylationR-HSA-74259:Purine catabolismR-HSA-1442490:Collagen degradation
|
Assembly of collagen fibrils and other multimeric structures
|
EPH-ephrin mediated repulsion of cellsR-HSA-1237044:Erythrocytes take up carbon dioxide and release oxygen
|
Reversible hydration of carbon dioxideR-HSA-1251985:Nuclear signaling by ERBB4
|
Regulated proteolysis of p75NTR
|
NRIF signals cell death from the nucleus
|
Activated NOTCH1 Transmits Signal to the Nucleus
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
EPH-ephrin mediated repulsion of cells
|
WikiPathways
|
Reversible Hydration of Carbon Dioxide
|
Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes
|
Uptake of Oxygen and Release of Carbon Dioxide by ErythrocytesWP2770:Reversible Hydration of Carbon Dioxide
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in leukocytes - TarBase
|
miR-targeted genes in epithelium - TarBaseWP2770:Reversible Hydration of Carbon DioxideWP2877:Vitamin D Receptor Pathway
|
Regulation of Hypoxia-inducible Factor (HIF) by OxygenWP702:Metapathway biotransformation
|
Aflatoxin B1 metabolism
|
Estrogen metabolism
|
Benzo(a)pyrene metabolism
|
Tamoxifen metabolism
|
Tryptophan metabolism
|
Oxidation by Cytochrome P450
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
Nuclear Receptors Meta-Pathway
|
Farnesoid X Receptor Pathway
|
Vitamin D Receptor Pathway
|
Felbamate Metabolism
|
Lidocaine metabolism
|
Nifedipine Activity
|
Colchicine Metabolic Pathway
|
Irinotecan Pathway
|
Drug Induction of Bile Acid Pathway
|
Fatty Acid Omega Oxidation
|
Codeine and Morphine MetabolismWP619:Type II interferon signaling (IFNG)
|
Spinal Cord Injury
|
AGE/RAGE pathway
|
Effects of Nitric OxideWP2770:Reversible Hydration of Carbon DioxideWP2770:Reversible Hydration of Carbon Dioxide
|
Uptake of Oxygen and Release of Carbon Dioxide by ErythrocytesWP474:Endochondral Ossification
|
Activation of Matrix Metalloproteinases
|
Oncostatin M Signaling Pathway
|
Matrix MetalloproteinasesWP2857:Mesodermal Commitment Pathway
|
Endoderm Differentiation
|
Trans-sulfuration and one carbon metabolism
|
One Carbon Metabolism
|
miR-targeted genes in lymphocytes - TarBaseWP408:Oxidative Stress
|
Effects of Nitric Oxide
|
Metabolism of nucleotides
|
Selenium Micronutrient NetworkWP98:Prostaglandin Synthesis and Regulation
|
Arachidonic acid metabolism
|
Phase 1 - Functionalization of compounds
|
Eicosanoid Synthesis
|
Selenium Micronutrient NetworkWP474:Endochondral Ossification
|
IL1 and megakaryotyces in obesity
|
Mammary gland development pathway - Involution (Stage 4 of 4)
|
Degradation of collagen
|
TWEAK Signaling Pathway
|
Angiogenesis
|
Osteopontin Signaling
|
Matrix MetalloproteinasesWP98:Prostaglandin Synthesis and Regulation
|
Aryl Hydrocarbon Receptor
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
Integrated Pancreatic Cancer Pathway
|
Selenium Micronutrient NetworkWP2770:Reversible Hydration of Carbon Dioxide
|
Uptake of Oxygen and Release of Carbon Dioxide by ErythrocytesWP61:Notch Signaling Pathway
|
Signaling by ERBB4
|
Signaling by NOTCH3
|
Signaling by NOTCH4
|
Signaling by NOTCH1
|
Signaling by NOTCH2
|
Notch Signaling Pathway
|
Alzheimers Disease
|
Signalling by NGF
|
References |
REF 1 | Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331-68. |
---|
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7000). |
---|
REF 3 | Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. Epub 2010 Jul 13.Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. |
---|
REF 4 | Eur J Med Chem. 2008 Aug;43(8):1621-31. Epub 2007 Nov 17.Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. |
---|
REF 5 | Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. Epub 2007 Dec 11.A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
---|
REF 6 | Bioorg Med Chem. 2010 Jan 15;18(2):822-9. Epub 2009 Nov 27.Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. |
---|
REF 7 | Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. Epub 2008 Mar 6.High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. |
---|
REF 8 | J Nat Prod. 2009 Apr;72(4):725-31.Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. |
---|
REF 9 | Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. |
---|
REF 10 | Bioorg Med Chem. 2009 Feb 1;17(3):1290-6. Epub 2009 Jan 6.Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. |
---|
REF 11 | J Med Chem. 2006 Oct 5;49(20):6111-9.Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. |